Elotuzumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany) recommended or restricted elotuzumab, while AOTMIT (Poland) and DMC (Denmark) did not recommend it.
Assessment has run over 10.3 years, from 4 Feb 2016 at AWMSG (Wales) to 14 Jun 2026 at NYE METODER (Norway).
NYE METODER (Norway) changed its position: not recommended on 22 May 2022, recommended by 14 Jun 2026, after a resubmission.
No assessment is on file from HAS (France), PHARMAC (New Zealand), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for elotuzumab, 2 submissions were never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Against its own class, elotuzumab is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
7 distinct indication wordings are recorded for elotuzumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 13 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess elotuzumab, on 4 Feb 2016; AOTMIT (Poland) did not open a file until 16 Aug 2022 — a wide spread of 6.5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 7 years in total.
5 of the 8 agencies here assessed elotuzumab more than once, NYE METODER (Norway) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for elotuzumab.
The full ledger for elotuzumab reads 4 recommended, 4 not recommended, 2 non-submission and 2 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 16 Aug 2022 | Empliciti reimbursement recommendation | not recommended | source |
| NYE METODER (Norway) | 22 May 2022 | Kombinasjonsbehandling med lenalidomid og deksametason ved myelomatose. | not introduced | source |
| G-BA (Germany) | 16 Dec 2021 | Empliciti — benefit assessment §35a | added benefit: considerable (hint) | source |
| SMC (Scotland) | 9 Aug 2021 | In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior … | not recommended | source |
| PBAC (Australia) | 2021 | Relapsed and/or refractory multiple myeloma (RRMM) | Recommended | source |
8 further decisions for elotuzumab, across 7 agencies, are not shown here. They include the most recent record on file, 14 Jun 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- selinexor — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 13 decisions for elotuzumab from 8 agencies, 2016 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.